Detailed explanation of which four groups of people are not suitable for taking Dasatinib

Dasatinib (Dasatinib), as a second-generation BCR-ABL tyrosine kinase inhibitor, is widely used in the treatment of chronic myelogenous leukemia (CML) and Ph+acute lymphoblastic leukemia (Ph+ ALL) and other diseases. Although its targeting effect is clear and its efficacy is significant, it is not suitable for all patients. According to clinical medication experience and warnings in the instructions, there are four categories of people who need to pay special attention before taking dasatinib, and should even avoid using it to prevent aggravation of the condition or induction of serious adverse reactions.

The first category is patients with severe underlying cardiopulmonary diseases or previous pleural effusion. One of the common side effects of dasatinib is pleural effusion, which is more likely to occur in the elderly or patients with existing lung disease. It may cause serious complications such as dyspnea, pericardial effusion, and even pulmonary hypertension. If the patient has heart failure, COPD or pericardial disease, the risk of taking dasatinib will be significantly increased, and it is necessary to carefully evaluate whether to switch to other targeted drugs.

The second category includes patients with severe bone marrow suppression or combined infections. Dasatinib may inhibit hematopoietic function, leading to a decrease in white blood cells, platelets and other indicators. If the patient originally has poor bone marrow function or active infection, taking medication may further lead to low immunity, aggravation of infection, or even sepsis. Before treatment, the infection should be controlled first, and the stability of the blood picture should be assessed before deciding whether to take medication.

The third category is pregnant and lactating women who are not suitable for taking it. Studies have shown that dasatinib may have toxic effects on fetal development, so it is contraindicated during pregnancy and contraception should be used during concurrent use. Although there is no definite data on whether the drug will be excreted through breast milk during lactation, for safety reasons, it is recommended to stop breastfeeding to prevent the drug from affecting the baby's health.

Finally, dasatinib should also be contraindicated in patients allergic to its components. If rash, facial swelling or severe allergic reaction occurs while taking the drug, it indicates that the individual is intolerant to the drug and needs to stop taking the drug immediately and adopt an alternative treatment plan. The above group of people should fully inform their doctors about their medical history and undergo strict evaluation before using dasatinib to ensure the safety of treatment.

Reference materials:https://www.drugs.com/